Barclays Rates Twist Bioscience (TWST) buy, $95 Price Target
Barclays maintains a positive outlook on Twist Bioscience, setting a $95 price target, a 4.85% downside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Barclays rated Twist Bioscience Corporation ($TWST) "buy" with a $95 price target on June 24, 2026.
Since the rating, $TWST is up 11.9% after 1 week, down 1.2% after 1 month and up 45.3% to date (from the $91.35 close on Jun 24, 2026).
TWST
Twist Bioscience Corporation
Key Points
- Barclays reiterated its buy rating on Twist Bioscience (TWST) with a price target of $95 on June 24, 2026.
- Barclays's $95 price target implies 4.85% downside from Twist Bioscience Corporation's ($TWST) current $99.84 share price.
- Shares of Twist Bioscience traded near $85 on Wednesday, with a market cap of $5.3 billion and a 52-week high of $89.71.
- Insiders at Twist Bioscience, including CEO Emily Leproust, sold shares in June, while analysts maintain a strong buy consensus.
Get $TWST trade alerts by text
We text you when insiders, Congress or big funds trade $TWST. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Twist Bioscience Corporation alert may contain errors. Disclosures
Barclays has reiterated its buy rating on Twist Bioscience Corporation (NasdaqGS:TWST), maintaining a price target of $95. The update came from analyst Luke Sergott on June 24, 2026. Twist Bioscience shares were trading around $85 on Wednesday.
Barclays vs. the S&P 500
Hypothetical returns from Barclays's disclosed trades, not real profit or advice. How we model this.
Twist Bioscience Corporation Stock Down 30.9%
On Wednesday, shares of Twist Bioscience traded near $85. The company has a market capitalization of about $5.3 billion. Though not currently profitable, it has a forward P/E ratio of -111.6 and a beta of 2.214, indicating higher volatility compared to the market. Over the past year, the stock has seen a low of $23.30 and a high of $89.71. The 50-day moving average is $62.46, while the 200-day moving average stands at $43.19. Twist Bioscience has a current ratio of 2.696, a quick ratio of 2.036, and a debt-to-equity ratio of 24.36.
$TWST price target
Twist Bioscience Corporation daily closes and this analyst's $95 target. Not advice.
Recent Earnings
Twist Bioscience reported revenue of $409.5 million, with a growth rate of 19.3%. Despite this growth, the company is not yet profitable, with a net margin of -19.8% and a return on equity of -18.2%. The next earnings report is expected on August 3, 2026.
Insider Buying and Selling at Twist Bioscience Corporation
In recent insider activity, Paula Green, the SVP of Human Resources, sold shares twice on June 15, 2026, at prices of $0 and $81.66 per share. Additionally, she purchased shares at $23.33 on the same day. On June 8, 2026, CEO Emily Leproust and other insiders, including Dennis Cho, sold shares at $69.84.
Analysts Set New Price Targets
Barclays maintained its buy rating with a $95 target on June 24, 2026. Other analysts have also shown confidence in Twist Bioscience. On June 15, TD Cowen maintained a buy rating with an $89 target, and Canaccord Genuity initiated coverage with a buy rating and a $90 target. Piper Sandler also initiated a buy rating with an $85 target on June 11.
About Twist Bioscience
Twist Bioscience Corporation, based in South San Francisco, California, develops and sells synthetic DNA-based products. Founded in 2013, the company serves the healthcare, diagnostics, and research sectors. Led by CEO Dr. Emily Marine Leproust, Twist Bioscience provides synthetic genes, DNA libraries, and NGS tools, among other products, to support various applications in academic and industrial settings. The company employs 979 people.
Bottom Line
Barclays' reiteration of its buy rating for Twist Bioscience highlights continued confidence in the company's growth potential. Investors often track such analyst insights for guidance, though it's important to remember that these ratings reflect past performance and expectations. As Twist Bioscience continues to innovate in the synthetic DNA space, its financial metrics and market position will be closely watched.
Related Filing Alerts
Source: Barclays's rating change on $TWST (Jun 24, 2026). Written by software, not financial advice. How we make alerts